New treatment for Schizophrenia/Nuevo tratamiento para la Esquizofrenia
-
Upload
braincosm -
Category
Health & Medicine
-
view
556 -
download
0
description
Transcript of New treatment for Schizophrenia/Nuevo tratamiento para la Esquizofrenia
H Bfrin
Hypothesis:
BRAINco harom schizopnvolved in n
The modu
as carried ophrenic patneurotransm
ulation of ne
Refne
BRAINco
New
Exocy
Advant
• A
o
• A
p
v
• M
out extensivtients that h
mitter releas
eurotransm
ATPDocking
filling withurotransmitter
o target
Sy
treatmytosis mod
tages:
A novel me
on neurotr
A novel the
postmortem
validated i
Molecules
ve genomic had commi
se have been
mitter relea
Ca
Neurotrreceptor
Priming
Ca2+
s
ynaptic vesicles
LICE
ment for dulators f
echanism
ransmissio
erapeutic
m brain fr
in unique c
modulatin
and proteoitted suicidn found in th
ase may pla
a2+
ansmitterr
Fusion
+
H+
s
ENSIN
Schizofor the tre
of action:
on.
target whi
rom schizo
cellular an
ng the syst
omic analysde. Increaseheir prefron
ay a crucial
Ca2+
Early en
E
NEUROT
NG OPP
phreniaeatment of
the exocyt
ich has bee
phrenic pa
nd transge
tem have a
is of humand expressio
ntal cortex.
l role in the
Syn
Presy
Posts
ndosome
Endocytosis
H+
TRANSMISSIO
PORTU
a of Schizop
tosis impli
en found al
atients, and
enic anima
already be
n postmorteon levels o
e future of
naptic Cleft
ynaptic membra
synapticmembra
ON
UNITY
phrenia
icated dire
ltered in h
d has been
al models.
een identif
em brain tisf a key pro
antipsycho
ne
ane
Y
ectly
human
fied.
ssues otein
otics.
BAC
BRAin viveffic
TOO
A relfrom Thengene
Cel
Severeleabioel
Sevetissu
Targeident
CKGROUN
AINco aims tvo models anacy in the tra
Exocytosisspecific: dBRAINco is based on
OL GENER
levant incream Schizophren
n, BRAINco erated for val
ll based assa
eral cellular base with diffelectrical assa
The effect ousing severaresults fromThe radioactvalidated forA fluorescenbeing adapte
eral assays ine specificity
et tification
ND
o validate thnd find moleansgenic anim
s takes placedifferent isofo
expects to ann neuronal c
RATION A
ase of the targnia subject, m
has validatelidation will b
ay:
based assays erent read-ouays:
f target on exal cellular ba
m the radioacttive assay har screening nt assay baseed to HCS.
n cell lines de.
In smo
Assay development
Animal model
he implicationcules with a mal over exp
in almost evforms are expnticipate mo
cellular mod
AND TARG
get has beenmodulated by
d the target abe used to de
have been suts: radioact
xocytosis haased assays, ative assay in as been adapt
ed on a mole
erived from d
Devel
Target validation
silicoodeling
n of the targegood preclin
pressing the t
very tissue hopressed depenolecules specdels, 2) Targe
Figure 1
GET VALI
n found in humby antipsycho
at animal andevelop the pr
et up to meaivity, fluores
as been validaas an examplFig.2. ted to HTS a
cular probe i
different peri
lopmen
Virtual screening
Primary assay
et in the etiopnical profile target of inte
owever the pnding on theificity issues
et focused ap
1: Workflow of th
DATION
man postmootic treatmen
d cellular levroject.
asure neurotrascent probes
ated le
and
is
ipheral tissue
nt Stage
Screening campaing
In‐vitro testing
Mole
B
pathogenia othat affect ne
erest.
proteins invoe cell type. s combining pproach done
he project
rtem brain nt (Fig.1).
vels, the tools
ansmitter and other
es have been
e: Cand
Hit toLead
ecule testing
Biomarker dis
Figure 2. Neuroand right: when
of the diseaseeurotransmit
olved in this m
two strategiee with specifi
s
n set up in ord
idate Id
Figure 1. tissue.
Lead Opt.&
scovery
otransmitters relean target is knocke
e using in vittter release an
machinery a
es: 1) Cell bafic isoforms f
der to evalua
dentific
Target expression
Candipreclidevel
ase, left: when tad down.
tro as well asnd present
are tissue
ased approacfrom the bra
ate molecule
ation
n in brain post mo
idate for inicallopment
rget is overexpre
s
ch ain.
s
ortem
ssed
Tra
An anBehavschizo
We befo
CAN
Cel
Sever
Tar
A viridenti
Fig(tre
ansgenic (TG
nimal modelvioral, morpophrenia like
Behavio
Increase iactivity (o
Social int Deficit in
(prepulse Deficit in
(new obje
are aiming aore the end o
NDIDATE F
lular based
ral chemicalA screeningidentified rA second shas been ouA third scre
rget focused
rtual screenintified in the t
A preliminavalidate boA virtual scperformed.protein inte
gure 3. Deficit in eated with antipsy
G) animal m
l over-expreshological, bie phenotype.
oral
in locomotioopen field). teraction defen sensoring g
inhibition) Fn working meect recognitio
at in vivo Proof the year.
FINDING
approach:
l starting poig with the Prrepresent oracreening witutlined. eening is bei
d approach:
ng has been ptarget by in sary virtual scth sites. creening with The molecu
eraction assay
PPI in TG mice ychotic)
model:
ssing the targiochemical a.
n
fects. ating Fig.3. emory on).
oof of Conce
ints have beerestwick librally availableth a diverse l
ing planned w
performed agsilico modelicreening has
h millions ofules obtainedy adapted to
Devel
rget of intereand molecula
ept of the can
en identifiedary (1120 FD drugs. library (9652
with a differe
gainst two dring. been perform
f compoundsd will be teste
HTS (the H
lopmen
Figure 4. Chanvolume betwee
Morph
Brain vo Reductio
tracks. Increase
(Fig.4).
st has been gar characteriz
ndidates in ou
d so far. DA approval
2 compounds
ent methodo
ruggable site
med in order
s is now beined in a proteiTRF assay F
nt Stage
nges in brain and en WT and transg
hological alt
olume decreaon in white m
e in ventricle
generated. zations have
ur animal mo
l compounds
s) has been d
logy and a la
es
r to
ng in-
Fig.6).
e: Cand
Fventricles genic
teration
ase. matter
volume
Figurconce
shown that t
odel and oth
) has been pe
done and a sp
arger and mo
idate Id
Figure 5. LTP TG
Func
Reduc Altera
system Abnor
oscilla
e 6. HTRF assay entrations and dif
transgenic m
er classical a
erformed and
pecific chemi
ore diverse lib
dentific
G vs. Control (C5
ctional
ction in long ation of neuroms. rmality in baatory activity
Target/ Target pfferent fluorescen
mice present a
animal mode
d the hits
ical family
brary.
ation
57 & CBA/C57)
term potentiotransmitter
sal cortical y (Fig.5).
partner (different t TAGs)
a
els
iation.
Su
ScsHa Btcrc BNdrfit Ioedp
ummarize
Schizophrencost reachesymptoms, However, alaction
BRAINco hissues from
certain proteresearch grocomplex dis
BRAINco hNowadays tdeveloped drelease of nefor one part,ts main part
In addition, others diseaencephalopadifferent tispatient strati
nia is currened €35 bill
together wlmost none
has carried m schizophreeins involveoups have sorder.
has built uthe target hdifferent ceeurotransmi, the mechatner involve
the expressases. At genathy. BRAINsues, includification.
ntly estimatlion. Curre
with their se of the pre
out extensenic patiented in exocytfurther sup
up a drug as been val
ellular and itters. BRA
anism of exoed in this m
sion of the netic level, mNco will asding the an
BRAINcEdificio 50jmasse@
ted to affectnt antipsycide effects,
esent drugs
sive genomits that had ctosis have b
pported thes
discovery lidated at hbiochemica
AINco set upocytosis and
mechanism.
target has amutations inssess the bi
nimal mode
co Biopharma4. Parque tecnológi
@brainco.es |
t around 1.chotics lack, has stressunder deve
ic and protcommitted sbeen found ise findings
program buman, animal assays up two approd for a seco
already beenn the target iochemical
el, as well a
a S.Lico de Vizcaya | 48 www.brainco
1% of the Uk of efficased the neelopment ar
teomic analsuicide. Altin the prefro, involving
based on emal and cellsed for fin
oaches in orond part, the
n found altehave also band functio
as patients
8160 Derio (Bilbao).o.es
US populatiacy particued for morre based on
lyses of huterations in ontal cortex the exocy
exocytosis lular levels.
nding molecrder to find e interaction
ered in Schbeen identifonal alteratiin order to
. Vizcaya. Spain | T
ion and its tularly againre effectiven a new me
uman postmthe express
x of these paytosis mach
and neurot. The compcules that mmolecules
n between t
hizophrenia fied in infanion of the e
o define the
elf: +34 94 406452
total medicnst cognitive treatmentechanisms o
mortem braision levels oatients. Othe
hinery in th
transmissionpany has alsmodulate ththat regulahe target an
as well as intile epileptexocytosis ie strategy fo
5 | Fax: +34 94 40
al ve ts. of
in of er
his
n. so he te
nd
in ic in or
06 4526